Zhu Xuming, Zhou Hongxing
Department of Laboratory Medicine, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, People's Republic of China.
Department of Laboratory Medicine, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, People's Republic of China.
J Hepatocell Carcinoma. 2022 Oct 29;9:1127-1136. doi: 10.2147/JHC.S387189. eCollection 2022.
Identifying cirrhotic hepatocellular carcinoma (HCC) during liver cirrhosis (LC) stage is pivotal for improving the clinical outcomes of cirrhotic HCC patients. Inflammation-driven markers play a crucial role in tumorigenesis and tumor progression. Neutrophil-to-lymphocyte ratio (NLR) is an inflammatory response marker. This study aimed to evaluate the ability of NLR to distinguish cirrhotic HCC from LC.
Data of healthy control (HC) people, LC patients, cirrhotic HCC patients, and non-cirrhotic HCC patients were retrospectively analyzed. Mann-Whitney test and Chi-squared test were used to compare demographic and clinical parameters in different groups. Spearman correlation analysis was used to assess correlations. Receiver operating characteristic (ROC) curves were performed to determine diagnostic accuracy.
A total of 419 participants were enrolled in this study, including 152 HC people, 131 LC patients, 96 cirrhotic HCC patients, and 40 non-cirrhotic HCC patients. Level of NLR was elevated significantly in LC compared with HC ( < 0.001). No significant differences were found for NLR between LC and cirrhotic HCC ( = 0.083), as well as between cirrhotic HCC and non-cirrhotic HCC ( = 0.729). NLR was positively correlated with platelet-to-lymphocyte ratio ( = 0.33, < 0.001). The area under the ROC curve (AUC) value for NLR to distinguish LC from HC was 0.759 ( < 0.001), and AUC value to distinguish cirrhotic HCC from LC was 0.567 ( = 0.083), and AUC value to distinguish non-cirrhotic HCC from cirrhotic HCC was 0.519 (0.415-0.623) ( = 0.729).
NLR can distinguish LC from HC but cannot not distinguish cirrhotic HCC from LC.
在肝硬化(LC)阶段识别肝硬化肝细胞癌(HCC)对于改善肝硬化HCC患者的临床结局至关重要。炎症驱动的标志物在肿瘤发生和肿瘤进展中起关键作用。中性粒细胞与淋巴细胞比值(NLR)是一种炎症反应标志物。本研究旨在评估NLR区分肝硬化HCC与LC的能力。
回顾性分析健康对照(HC)人群、LC患者、肝硬化HCC患者和非肝硬化HCC患者的数据。采用Mann-Whitney检验和卡方检验比较不同组的人口统计学和临床参数。采用Spearman相关分析评估相关性。绘制受试者工作特征(ROC)曲线以确定诊断准确性。
本研究共纳入419名参与者,包括152名HC人群、131名LC患者、96名肝硬化HCC患者和40名非肝硬化HCC患者。与HC相比,LC患者的NLR水平显著升高(<0.001)。LC与肝硬化HCC之间的NLR无显著差异(=0.083),肝硬化HCC与非肝硬化HCC之间的NLR也无显著差异(=0.729)。NLR与血小板与淋巴细胞比值呈正相关(=0.33,<0.001)。NLR区分LC与HC的ROC曲线下面积(AUC)值为0.759(<0.001),区分肝硬化HCC与LC的AUC值为0.567(=0.083),区分非肝硬化HCC与肝硬化HCC的AUC值为0.519(0.415 - 0.623)(=0.729)。
NLR可区分LC与HC,但不能区分肝硬化HCC与LC。